STAAR Surgical Company（STAA）今日盘中大幅上涨25.14%，引起了市场的广泛关注。
消息面上，此次股价大涨主要受到两方面利好消息推动。首先，Canaccord Genuity将STAAR Surgical的股票评级从“持有”上调至“买入”，同时将其目标价从22美元上调至27美元，这反映了机构对公司未来前景的乐观看法。
其次，公司公布的2026年第一季度初步净销售额指引表现强劲。预计第一季度净销售额将超过9000万美元，较2025年同期的4260万美元增长超过一倍，并大幅超出分析师平均预期的7300万美元。这一增长主要得益于中国市场的强劲反弹以及美洲市场的持续两位数增长，显示出公司核心业务的强劲复苏势头。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.